A U.K. government regulator says certain cannabis products can be considered medicine, in a big win for the campaign to legalize cannabis use.

The decision from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) applies to products containing Cannabidiol (CBD), a specially bred variety of cannabis that has extremely low levels of the hallucinogenic drug THC, meaning it does not cause a high but is thought to retain the same health benefits of other forms of cannabis.

The MHRA review found that CBD has a “restoring, correcting or modifying” effect on “physiological functions” when administered to humans, the U.K.’s Independent reports.

“We have come to the opinion that products containing cannabidiol (CBD) are a medicine,” said the MHRA, in a statement to TIME. “Products for therapeutic use must have a medicines’ licence before they can be legally sold, supplied or advertised in the UK. Products will have to meet safety, quality and effectiveness standards to protect public health.”

The government’s review came about as a result of discussions between the MHRA and CBD vaporizer company MediPen, the Independent reports.

“Since our inception we’ve worked hard to obtain our goal of breaking down the negative connotations surrounding cannabis to lead to a reform in the law for medicinal use,” Jordan Owen, MediPen’s managing director, told the Independent. “Now this is finally becoming a reality.”

Get our Health Newsletter. Sign up to receive the latest health and science news, plus answers to wellness questions and expert tips. Please enter a valid email address. Sign Up Now Check the box if you do not wish to receive promotional offers via email from TIME. You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Thank you! For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Write to Kate Samuelson at kate.samuelson@time.com.